Activates the JUN N-terminal pathway through activation of the MAP kinase kinase MAP2K7. Acts synergistically with PRDX3 to regulate the activation of NF-kappa-B in the cytosol. This activation is kinase-dependent and involves activating the IKK complex, the IKBKB-containing complex that phosphorylates inhibitors of NF-kappa-B.

The stated application concentrations are suggested starting points. Titration of the MAP3K13 antibody may be required due to differences in protocols and secondary/substrate sensitivity.

A portion of amino acids 52-305 from the human protein was used as the immunogen for the MAP3K13 antibody.

Aliquot the MAP3K13 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.